Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.90 |
| ▸ | GRM6 | O15303 | 2/20 | 0.90 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.90 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.90 |
| ▸ | GSR | P00390 | 2/20 | 0.90 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.90 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.90 |
| ▸ | GRM5 | P41594 | 1/20 | 0.90 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.90 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.90 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.90 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.90 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.90 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.90 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.90 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.90 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.90 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL1554237 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL1332297 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL17127348 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL248800 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL2201 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL410241 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL5704264 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL1330824 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL931953 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL1330484 | 0.95 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100411518-C | Antiseptics for improving hydrogen peroxide sterilizing activity and preparing process thereof | LASA LUNENG SCIENCE & TECHNOLO (CN) | 2008-08-20 | — | — | CN | claimed |
| CN-109402164-B | Method for overexpression of squalene epoxidase gene in alfalfa and application | 中国农业科学院北京畜牧兽医研究所 | 2020-09-25 | — | — | CN | disclosed |
| CN-108290919-A | Azithromycin derivatives having epithelial barrier enhancing properties | 艾比恩多制药有限责任公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-105777790-B | A kind of adjacent carborane phenol derivatives and its preparation method and application | 南京远淑医药科技有限公司 | 2017-11-14 | — | — | CN | disclosed |
| CN-100411518-C | Antiseptics for improving hydrogen peroxide sterilizing activity and preparing process thereof | LASA LUNENG SCIENCE & TECHNOLO (CN) | 2008-08-20 | — | — | CN | disclosed |
| CN-100360554-C | peptide conjugates | UNIV KEIO (JP) | 2008-01-09 | — | — | CN | disclosed |
| CN-1747967-A | Peptide conjugate | UNIV KEIO (JP) | 2006-03-15 | — | — | CN | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| CN-1060775-C | Fused tropane-derivatives as neurotransmitter reuptake inhibitors | NEURORES AS (DK) | 2001-01-17 | — | — | CN | disclosed |
| CN-1201461-A | Fused tropane-derivatives as neurotransmitter reuptake inhibitors | NEURORESEARCH A S (DK) | 1998-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | GRM8 4006/4885GRM6 3185/4885GRM7 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.